Pimavanserin

71 interactions 3 explained in plain English
Also sold as: Nuplazid Nuplazid®
About Pimavanserin

Pimavanserin is used to treat hallucinations and delusions in people with psychosis from Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance). Pimavanserin is in a class of medications called atypical antipsychotics. It works by changing the acti… Read the full Pimavanserin drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Metoclopramide Injection Ketoconazole Topical Metoclopramide Nasal Spray Lefamulin Lenvatinib Oxaliplatin Injection
4 Contraindicated 67 Major
All (71) Contraindicated (4) Major (67)

Contraindicated

Pimavanserin Ketoconazole Topical Extina® Foam Increased pimavanserin exposure and an increased risk of QT interval prolongation Details Pimavanserin Lefamulin Xenleta Increased sensitive CYP3A4 substrates exposure and an increased risk of QT interval prolongation Details Pimavanserin Metoclopramide Injection Gimoti An increased risk of extrapyramidal reactions and neuroleptic malignant syndrome Details Pimavanserin Metoclopramide Nasal Spray Gimoti An increased risk of extrapyramidal reactions and neuroleptic malignant syndrome Details

Major

Pimavanserin Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Pimavanserin Sertraline Explained An increased risk of QT interval prolongation Details Pimavanserin Buprenorphine Belbuca Explained An increased risk of QT interval prolongation Details Pimavanserin Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Pimavanserin Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Pimavanserin Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Pimavanserin Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Pimavanserin Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Pimavanserin Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Pimavanserin Azithromycin AzaSite An increased risk of QT interval prolongation Details Pimavanserin Cabergoline Dostinex® Reduced efficacy of cabergoline and reduced efficacy of dopamine-2 receptors Details Pimavanserin Alfuzosin UroXatral An increased risk of QT interval prolongation Details Pimavanserin Anagrelide Agrylin An increased risk of QT interval prolongation Details Pimavanserin Bedaquiline Sirturo An increased risk of QT interval prolongation Details Pimavanserin Chloroquine Aralen® An increased risk of QT interval prolongation Details Pimavanserin Dasatinib Phyrago An increased risk of QT interval prolongation Details Pimavanserin Degarelix Injection Firmagon An increased risk of QT interval prolongation Details Pimavanserin Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Pimavanserin Disopyramide Norpace An increased risk of QT interval prolongation Details Pimavanserin Dofetilide Tikosyn An increased risk of QT interval prolongation Details Pimavanserin Dolasetron Anzemet An increased risk of QT interval prolongation Details Pimavanserin Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Pimavanserin Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Pimavanserin Encorafenib Braftovi Increased risk of QT interval prolongation Details Pimavanserin Entrectinib Rozlytrek An increased risk of QT interval prolongation Details Pimavanserin Eribulin Injection Halaven An increased risk of QT interval prolongation Details Pimavanserin Famotidine Calmicid An increased risk of QT interval prolongation Details Pimavanserin Famotidine Injection Calmicid An increased risk of QT interval prolongation Details Pimavanserin Felbamate Felbatol An increased risk of QT interval prolongation Details Pimavanserin Flecainide Tambocor® An increased risk of QT interval prolongation Details Pimavanserin Foscarnet Injection Foscavir An increased risk of QT interval prolongation Details Pimavanserin Fostemsavir Rukobia Increased risk of torsade de pointes Details Pimavanserin Galantamine Razadyne An increased risk of QT interval prolongation Details Pimavanserin Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation Details Pimavanserin Gemifloxacin Factive An increased risk of QT interval prolongation Details Pimavanserin Glasdegib Daurismo Increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.